AGIOS PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 |
| Operating income | -$472.1M | -$425.7M | -$391.5M | -$389.0M | -$378.4M |
| Cost of revenue | $6.3M | $4.2M | $2.9M | $1.7M | $0 |
| Cash from operations | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M |
| Capital expenditure | $4.3M | $1.7M | $999,000 | $4.9M | $5.7M |
| Free cash flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M |
| Share repurchases | — | — | $0 | $0 | $802.5M |
| Total assets | $1.3B | $1.7B | $937.1M | $1.2B | $1.4B |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M |
Shares outstanding 59.5M · Free float 87.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.